Skip to main content
Caplight Logo









Nura Bio

Nura Bio

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://nurabio.com/

Last Round

Series B

Jun 22, 2026

Total Funding Raised

$214.8M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Nura Bio is a biotechnology company that develops neuroprotective therapies aimed at preventing neuronal loss and enhancing immune function in the nervous system following neurological injuries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

neuroprotective therapyneurodegenerative diseaseSARM1 inhibitoraxonal degenerationsmall molecule drugbiotech startupclinical-stage biotechALS treatmentdrug discoverybrain drugsbiopharmatherapeutic pipelinenerve cell protection

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nura Bio Comparables

Compare Nura Bio with similar companies based on industry and business-model similarity.

Nura Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tenvie Therapeutics
89%
Sironax
87%
QurAlis
83%

Nura Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 22, 2026
Series A ExtensionSep 17, 2024
Series AJul 29, 2020

Key People

Founding team and executive leadership

Shilpa Sambashivan

Chief Executive Officer, Chief Scientific Officer

Executive Team

Bryan Miller

Interim CFO

Executive Team

Nura Bio Investors

Notable investors and investment history

Nura Bio investors
InvestorRounds
The Column GroupSeries A, Series B, Series A Extension
The Chernin GroupSeries A, Series A Extension
Sanofi VenturesSeries B, Series A Extension
Samsara BioCapitalSeries A, Series B, Series A Extension
Euclidean CapitalSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors increased 56% MoM.

  • Jun 22, 2026

    $74M round led by The Column Group.

Nura Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nura Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nura Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range34
Year Founded2018
Last FundingJun 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?